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Summary  
Inflammasomes are protein complexes that form in response to pathogen- or host-
derived stress signals. Their activation leads to the production of inflammatory 
cytokines and promotes a pyrogenic cell death process. The massive release of 
inflammatory mediators that follows inflammasome activation is a key event in 
alarming innate immune cells. Growing evidence also highlights the role of 
inflammasome-derived cytokines in shaping the adaptive immune response, as 
exemplified by the capacity of IL-1β to support Th17 responses, or by the finding 
that IL-18 evokes antigen-independent IFN-γ secretion by memory CD8+ T cells. A 
deeper understanding of these mechanisms and on how to manipulate this powerful 
inflammatory system therefore represents an important step forward in the 
development of improved vaccine strategies.  
 
 
Highlights:  
• inflammasome activation leads to production of bioactive IL-1β and IL-18 
• IL-1β promotes Th17 differentiation, IL-18 supports IL-12-driven Th1 
polarization 
• IL-18 drives non-cognate lymphocyte activation, thereby improving immunity 
• manipulation of inflammasome activity and substrates can ameliorate vaccine 
strategies 
 
Keywords:  
NLR; inflammasome; IL-1; IL-18; adjuvant; antigen-dependent T cell response; 
antigen-independent T cell response 
 
Glossary: 
AIM2, absent in melanoma 2; ASC, apoptosis speck protein with caspase 
recruitment domain; DAMP, danger-associated molecular pattern; ICSBP, interferon 
consensus sequence binding protein; NLR, NOD-like receptor; NLRC, NLR family, 
caspase recruitment domain containing; NLRP, NLR family, pyrin domain 
containing;	  PAMP, pathogen-associated molecular pattern; TCR, T cell receptor 
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Introduction  
Sensing of different PAMPs or DAMPs can lead to activation of inflammasomes 
[1,2]. The huge inflammatory potential liberated upon inflammasome assembly is a 
basic defense mechanism employed to control different infections and its central role 
in innate immune responses has been largely demonstrated over the past years. 
Mounting evidence suggests that inflammasomes might be important for adaptive 
immune responses as well. We will therefore present here the current understanding 
on how inflammasomes tailor adaptive immune responses. 
 
Inflammasomes: intracellular platforms for caspase-1 activation 
Inflammasomes are intracellular caspase-1 activating multiprotein complexes that 
are induced by different PAMPs or DAMPs (as schematically represented in Figure 1; 
for general review on inflammasome function, see [1,2]). They are formed by 
association of NLR family members with the adaptor protein ASC and procaspase-1 
through homotypic domain interactions. Their formation results in the proteolytic 
activation of caspase-1, which in turn processes different substrates. Several NLRs, 
such as NLRP1, NLRP3 and NLRC4 have been shown to form functional 
inflammasomes in response to a wide array of stimuli. Furthermore AIM2, a member 
of the PYHIN family, can recruit ASC and caspase-1 in response to double-stranded 
DNA [2].  
 
Regulation of caspase-1-dependent cytokines 
Active caspase-1 has several known targets, including cytokines from the 
interleukin (IL)-1 family. In addition, its activity is implicated in the unconventional 
secretion of other danger signals, such as the alarmin high-mobility group box 1 
(HMGB1), and in a process of inflammatory cell death called pyroptosis [3-5].  
IL-1β and IL-18, the two best-characterized inflammasome-dependent cytokines, 
are cleaved by caspase-1 from their inactive intracellular precursors, pro-IL-1β and 
pro-IL-18 [6]. IL-1α, another IL-1 family member, does not however require cleavage 
for its activity. It is often secreted concomitantly with IL-1β, though its release in 
response to certain stimuli and in vivo can be independent of the inflammasome [7,8]. 
Since IL-1α and IL-1β both signal through the IL-1R complex, the contribution in 
vivo of both cytokines is not always clear. It is therefore important to keep in mind 
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that dependency on IL-1R does not yet imply caspase-1 dependency. IL-18 signals via 
a distinct receptor, the IL-18R, which belongs to the IL-1 receptor superfamily and is 
structurally very similar to IL-1R. 
In contrast to IL-1, whose expression requires an NF-κB activating signal, IL-18 
mRNA is considered to be constitutively expressed in many cell types and therefore 
largely regulated through caspase-1-dependent cleavage [9]. However, LPS treatment 
of macrophages strongly augments IL-18 transcript abundance [10]. Notably, a PU.1 
and an ICSBP binding site have been located in the promoter of IL-18, which suggests 
its upregulation also by IFNs [11,12]. As type I IFNs can significantly reduce pro-IL-
1α and pro-IL-1β levels [13], it is plausible that IFNs shift the balance of the two 
major caspase-1 substrates in favor of pro-IL-18.  
 
Main effects of IL-1β  and IL-18 on T helper cell polarization  
The most prominent feature of IL-1β with regard to the adaptive immune response 
is to favor T helper type 17 (Th17) differentiation (as summarized in Figure 2) [14-16]. 
This lymphocyte subset secretes IL-17 and participates in host defense against 
extracellular bacteria and fungi, but is also involved in autoimmunity.  
IL-18 acts instead as an amplifier of IFN-γ production by Th1 cells (Figure 2) [11]. 
IL-18R is poorly expressed on naïve T cells, but is upregulated upon priming, 
allowing enhanced Th1 polarization of activated T lymphocytes. Furthermore, IL-18R 
expression is increased following exposure to IL-12, the major Th1-polarizing 
cytokine. IL-18, in turn, helps induce the IL-12 high affinity receptor, establishing a 
feed-forward Th1-amplifying loop [11,17]. Surprisingly, in the absence of a Th1-
polarizing environment, IL-18 can promote the differentiation of Th2 cells, a CD4+ T 
cell subset dominating allergic responses and characterized by the expression of IL-4 
and IL-13 [11,17,18]. 
 
Although the effects of IL-1β and IL-18 on adaptive immune cells have been well 
characterized, the in vivo relevance of inflammasomes in adaptive immune responses 
remains more elusive. The following sections will therefore summarize the recent 
data on their in vivo effects and pinpoint the drawbacks of the models that have been 
used.  
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INFLAMMASOMES AND ADJUVANTICITY 
 
Inflammasome activation and adjuvants  
It was long known that DAMPs can activate dendritic cells (DCs), thereby favoring 
T cell priming. Uric acid was identified, in a study by Rock and coworkers, as a 
danger signal released from dying cells that acts as an efficient T cell adjuvant [19]. 
Interestingly, DAMPs such as uric acid, ATP, or mitochondrial DNA activate the 
NLRP3 inflammasome, raising the question on whether or not its activity is important 
for T cell priming under such conditions. Indeed, uric acid crystals were shown to 
promote Th17 responses in an ASC- and caspase-1-dependent manner when applied 
subcutaneously [20]. However, in a uric acid-mediated asthma model Th2-polarized 
responses proceeded independently of the inflammasome [21].  
This is reminiscent of what has been observed for alum, a clinically approved 
adjuvant that is routinely used in human vaccines. Alum has unanimously been 
shown to activate the NLRP3 inflammasome in vitro, but the in vivo role of the 
inflammasome in alum-induced adjuvanticity remains controversial [22-26]. IL-18 
and IL-1 preferentially drive Th1/Th17 responses, whereas alum rather polarizes Th2 
type immunity, which – by some groups – was found to be unaltered in the absence 
of caspase-1 or Nlrp3 [24,25]. Along this line, whereas IL-1 signaling and 
inflammasome activity have been implicated in allergic reactions, the importance of 
the latter in the establishement of such Th2 responses has not been unambiguously 
delineated [26-28]. Therefore, the definitive role of the NLRP3 inflammasome in 
adjuvanticity might occur through indirect mechanisms, be strongly influenced by the 
context, and still remains to be clarified. 
Of note, it has been shown that tumor cells treated with chemotherapeutic agents 
can act as effective adjuvants to prime anti-tumor T cell responses through release of 
ATP and subsequent P2X7-dependent inflammasome activation [29]. As illustrated 
hereafter, additional implications of inflammasomes in the development of adaptive 
immunity come from the study of naturally occurring immune responses. 
 
Lessons from autoimmune and autoinflammatory conditions 
Recent reports link the inflammasome to Multiple Sclerosis (MS), a demyelinating 
inflammatory disease of the central nervous system, where autoreactive T cells target 
oligodendrocytes [30,31]. IL-1 signaling has been implicated in the development of 
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MS, a Th1- and Th17-driven pathology [30-32]. Inflammasome-deficient mice are 
protected from disease progression in experimental autoimmune encephalomyelitis 
(EAE), a mouse model of MS (Table 1) [33-36]. The exact function of the 
inflammasome in this process is however unclear, since two recent reports describe 
the implication of Nlrp3 and ASC in EAE progression [34,36], whereas another study 
finds an inflammasome-independent role for ASC [35]. These divergent findings 
could be due to differences in the immunization protocols used for EAE induction, as 
suggested in [33,36]. 
A second example is cryopyrin-associated periodic syndromes (CAPS), human 
disorders which present with recurrent fever and inflammation and are in many cases 
due to gain-of-function mutations in NLRP3 [37]. Knock-in (KI) mice harboring 
constitutively active NLRP3 mutations have been established and recapitulate several 
aspects of the human disease, such as skin and systemic illness together with 
increased IL-1β production in the myeloid compartment [38,39]. The NLRP3-
R258W KI mouse develops skin inflammation with neutrophil infiltration and 
predominant Th17 differentiation, whereas in the NLRP3-A350V KI mouse the 
autoinflammatory process was shown to be T and B cell-independent. The reason for 
these different observations in the two KI models remains unclear. Interestingly, a 
recent study showed increased IL-17 serum levels as well as Th17 frequency in 
CAPS patients, which could be reduced by blocking IL-1β in vivo, suggesting that 
inflammasome-derived IL-1β is important in the differentiation of Th17 in human 
autoinflammatory conditions (Table 1) [40]. 
 
Inflammasomes and T cell responses in infections 
IL-1 has been shown to promote Th17 polarization in the context of different types 
of infections (Table 1) [41-46]. The use of knockout mouse strains highlighted the 
role of caspase-1 and ASC in Th17 priming during Candida albicans infection [42]. C. 
albicans-induced IL-1β drives the differentiation of Th17 cells secreting IL-17 
alongside with IFN-γ [47]. In line with this observation, the absence of IL-1 often 
leads to decreased numbers of IL-17- as well as IFN-γ-producing cells [41-44]. 
Moreover, IL-1 can promote T cell proliferation, and its suppressive effects on 
regulatory T cells and IL-10 production by T cells provide a mechanistic 
interpretation for the former observation [47,48]. It is therefore not surprising that in 
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some infectious models, inflammasome deficiency leads to a generalized reduction of 
T cell responses [42,44]. In addition, it has recently been demonstrated that upon 
influenza A infection, IL-1R signaling in DCs is necessary to promote CD8+ T cell 
responses, illustrating how paracrine IL-1 can contribute to mature DCs [49]. Since 
this study was based on IL-1RI-knockout mice, the precise contribution by 
inflammasomes, however, remains to be determined.  
Bordetella pertussis infection of IL-1RI-deficient animals showed decreased 
protection and diminished Th17 responses [43]. Yet, because both IL-1β and IL-1α 
promote Th17 polarization, the contribution by the inflammasome in the priming 
phase was shown using a selective caspase-1 inhibitor. The use of Nlrc4- and Nlrp3- 
further suggested inflammasome relevance in inducing Th17 responses upon 
Legionella pneumophila and Schistosoma mansoni infection, respectively [44,45]. In 
contrast, caspase-1 ablation did not reduce IL-17 production in the context of 
Helicobacter pylori infection, while IL-18 deficiency promoted it, pinpointing the 
relevance of inflammasome substrates in modulating the adaptive immune response 
[41].  
IL-18 has been shown to promote IFN-γ production in several infectious models, 
including Propionibacterium acnes, Mycobacterium bovis, Leishmania major, and the 
intracellular fungal parasite Cryptococcus neoformans [11,50]. However, it was 
noticed early on that the effects of IL-18 on Th1 polarization are different from those 
of IL-12. While IL-12 is a crucial factor for Th1 polarization, IL-18 only has the 
ability of acting on IL-12-primed cells to strengthen their Th1 differentiation [50].  
Infectious models make a strong case for the in vivo Th17/Th1 polarizing 
properties of the inflammasome substrates IL-1β and IL-18. As discussed in the next 
section, IL-18 also owns the surprising ability to elicit IFN-γ secretion by memory T 
cells in the absence of antigenic-triggering, questioning – in some experimental 
settings – its factual contribution to bona fide Th1 polarization. 
 
Inflammasome and non-cognate lymphocyte activation 
Recent findings highlight inflammasome importance in mediating non-cognate 
IFN-γ release, thereby “adjuvating” immune responses (illustrated in Figure 3). 
Salmonella Typhimurium infection or injection of heat-inactivated lysates stimulated 
the release of IFN-γ by splenic memory cytotoxic T cells of unrelated specificity [51]. 
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This effect, as shown by the use of knockout mice, was mediated by IL-18 released 
upon NLRC4 inflammasome activation in DCs as early as two hours after the insult. 
Importantly, non-cognate CD8+ T lymphocyte-derived IFN-γ contributed to the 
management of the infection [51]. Similarly, splenic natural killer (NK) and memory 
CD8+ T cells produced innate IFN-γ secretion starting from eight hours after Listeria 
monocytogenes infection [52]. Inflammatory monocytes were the key cells eliciting, 
in a caspase 1-dependent manner, lymphocyte-derived IFN-γ release, suggesting that 
different cell subsets could contribute to IL-18 secretion either sequentially or 
depending on the infectious agent. In addition, an analogous mechanism takes place 
in draining lymph nodes where, upon Pseudomonas aeruginosa infection, the major 
source of IL-18 are subcapsular sinus macrophages, which are strategically 
positioned to capture invading pathogens and particles [53]. Innate IFN-γ secretion by 
CD8+ T cells and other lymphocyte subsets was observed upon additional bacterial, 
viral, and protozoan infections, underlining how broadly this phenomenon might 
contribute to immune responses [51-53]. 
Recent studies attributed not only to IL-18, but also to IL-1β, in combination with 
IL-23 the ability to stimulate IFN-γ as well as IL-17 secretion without need for TCR 
triggering [30,54]. These results further suggest that inflammasome-driven innate 
lymphocyte functions could be relevant to antifungal and autoimmune responses.  
An environment rich in IFN-γ coinciding with antigen presentation to naïve T 
lymphocytes favors the priming of robust Th1 responses. The advantage of evoking 
IFN-γ production by lymphocytes could, therefore, be twofold: it helps to activate 
innate immune cells to control pathogen spread during primary encounter and the 
development of a Th1-polarized memory response for future challenges. 
 
Concluding Remarks  
While emerging evidence highlights the importance of inflammasome-derived IL-
18 to elicit innate IFN-γ secretion by lymphocytes, its impact on the concomitant 
priming of antigen-specific T cells has not been explicitly addressed. Furthermore, to 
carefully evaluate inflammasome relevance in the priming and polarization of 
adaptive immune responses, the contribution of the different inflammasomes, their 
substrates, and IL-1α should be individually addressed. The current understanding is 
in fact strongly hindered by the lack of such complete information. Hopefully, future 
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work will enable us to better define the role of each of these players.  
Nonetheless, the key role of IL-1 in supporting Th17 polarization and the 
importance of IL-18 in promoting Th1-tailored responses as well as non-cognate 
IFN-γ release are supported by multiple lines of evidence. The divergent functions of 
IL-1β and IL-18 in shaping adaptive immunity render the possibility of controlling 
these two substrates appealing, particularly for vaccination purposes. Favoring IL-18 
production represents a promising way to achieve protective Th1 responses. Type I 
IFNs are known to inhibit pro-IL-1 synthesis and activity of the canonical NLRP3 
inflammasome, while they might promote pro-IL-18 [11,13,32,55]. Thus, an 
attractive adjuvant could combine an inducer of type I IFN to an activator of an 
alternative inflammasome, such as the AIM2 inflammasome [2], maybe in the form 
of nucleic acids or safe viral agents. 
The last decade witnessed the discovery of inflammasomes as key players of the 
innate immune response and led to improved clinical treatments for 
autoinflammatory disorders. The role of inflammasomes in the adaptive immune 
response has only recently emerged and anticipates a better control of adaptive 
immunity over the coming years.  
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Tables and Figure Legends 
 
Table 1. Implications of inflammasomes in the development of adaptive immune 
responses in autoinflammatory, autoimmune, and infectious diseases. (n.a., not 
assessed; arrows in brackets indicate a mild effect) 
disease/infection model 
IFN-γ  
(Th1) 
IL-17 
(Th17) disease/experimental model  refs 
CAPS è,(ì) ì CAPS patients, NLRP3-R258W KI 40,38 
EAE 
(inact. M. tuberculosis/ 
pertussis toxin) 
î î caspase-1-/-, Asc-/- , Nlrp3-/-, IL-18-/- 30, 
33-36 î î IL-1RI-/- 
M. tuberculosis î n.a. AIM2-/- 46 
B. pertussis  
(adenylate cyclase toxin) (î),n.a. î IL-1RI
-/-, caspase-1 inhibitor 43 
C. albicans î î Asc-/-, caspase-1-/- 42 
L. pneumophila 
n.a. î caspase-1-/-, IL-1RI-/-, Nlrc4-/- 
45 
n.a. ì IL-18-/- 
S. mansoni î î Nlrp3-/-, Asc-/- 44 
H. pylori 
è (ì) caspase-1-/-, IL-18-/- 
41 
è è IL-1RI-/- 
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Figure 1. Schematic overview of the best-characterized inflammasomes and their 
main activators. 
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Figure 2. Effects of IL-1 and IL-18 in the polarization of T cell responses. 
IL-1β and IL-18 are processed into their active form by the inflammasome and can 
differentially influence the polarization of T cells. Whereas IL-18 supports Th1 
differentiation in synergy with IL-12, IL-1β promotes Th17 differentiation. IL-1α 
shares with IL-1β this ability, but its secretion can be independent of the 
inflammasome. 
 
 
  
	   14	  
Figure 3. Inflammasome-derived cytokines elicit non-cognate memory T cell 
effector functions. 
In the above-depicted infectious models, it was shown that inflammasome-derived 
IL-18 drives IFN-γ production by memory CD8+ T cells, even in the absence of TCR 
stimulation. Similarly, IL-1 together with IL-23 can elicit IL-17 secretion by 
activated CD4+ and CD8+ T cells in an antigen-independent manner. Furthermore, 
other lymphocyte subsets such as NK, NKT, or γδ T cells can respond to IL-18 and 
IL-1 contributing to the innate production of IFN-γ and IL-17. 
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